Perfluoroundecanoic acid
Based on 1 Customer Validation
Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 2058-94-8
- Formula: C11HF21O2
- Molecular Weight:564.09
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Perfluoroundecanoic acid (2-16 μM, 24 h) promotes M2 polarization of RAW264.7 macrophages by increasing the protein and mRNA levels of M2 markers (ARG1, CD163, TGF-β) and decreasing M1 marker (iNOS)[1].
Perfluoroundecanoic acid (8 μM, 24 h) activates Wnt/β-catenin signaling in RAW264.7 cells, enhancing β-catenin expression and nuclear translocation[1].
Perfluoroundecanoic acid (8 μM, 24 h)-pretreated RAW264.7 cell conditioned medium promotes migration and invasion of A2780 and SKOV3 ovarian cancer cells, which is reversed by β-catenin inhibitor ICG001 (HY-14428)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 cells
-
Concentration:2, 4, 8, 16 μM
-
Incubation Time:24 h
-
Result:Increased protein levels of M2 markers (ARG1, CD163) and decreased M1 marker (iNOS), with the most significant changes at 8 μM.
Increased β-catenin protein level and nuclear translocation; no significant changes in p-smad2, p-smad3, p-Akt, p-mTOR, or PPARα.
In Vivo
Perfluoroundecanoic acid (0-10 mg/kg, p.o., daily, 21-35 days) inhibits Leydig cell development and function via oxidative stress and autophagy in pubertal male Sprague-Dawley rats[2].
Perfluoroundecanoic acid (3-300 μg/L in drinking water, from mating through gestation, lactation and until 30 weeks of age) accelerates insulitis development in a mouse model of type 1 diabetes[3].
Perfluoroundecanoic acid (0.1-1.0 mg/kg, p.o., daily, 28-35 days) induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-week-old female BALB/c nude mice were intraperitoneally coinjected pretreated RAW264.7 cells and SKOV3 cells, with observation for 4 weeks[1]
-
Dosage:8 μM pretreated RAW264.7 cells
-
Administration:Co-injected intraperitoneally with SKOV3 cells for 4 weeks
-
Result:Increased the number and weight of ovarian cancer metastatic nodules.
Reduced the number and weight of ovarian cancer metastatic nodules in the above mouse model when pretreated with β-catenin inhibitor ICG001.
-
Animal Model:35 days old Sprague-Dawley rats[2]
-
Dosage:1, 5, 10 mg/kg
-
Administration:p.o. daily for 21-35 days
-
Result:Reduced serum testosterone at ≥1 mg/kg; no effect on serum estradiol.
Reduced serum LH at ≥1 mg/kg and serum FSH at 5 and 10 mg/kg.
Down-regulated expression of Lhb and Fshb in the pituitary at 5 and/or 10 mg/kg; up-regulated Gnrhr expression at 10 mg/kg.
Reduced Leydig cell number (CYP11A1-positive and HSD11B1-positive) at 5 and 10 mg/kg; no effect on Sertoli cell number.
Down-regulated expression of steroidogenesis-related genes (Lhcgr, Scarb1, Star, Cyp11a1) and their proteins in the testis at various doses.
Reduced sperm in the epididymis caput, corpus, and cauda at 10 mg/kg.
Increased testicular triglyceride levels at 5 and 10 mg/kg; no effect on testicular total cholesterol.
Down-regulated expression of Sod1 and Sod2 in the testis at various doses; increased MDA levels at 10 mg/kg.
Increased LC3B and p62 levels.
Reduced Beclin1 at 5 and 10 mg/kg.
Reduced phosphorylation of mTOR, AKT1, AKT2, and ERK1/2.
Reduced BCL2 levels at 5 and 10 mg/kg; increased BAX level at 10 mg/kg.
-
Animal Model:Female non-obese diabetic (NOD) mice (offspring of 8-week-old females and 10-week-old males)[3]
-
Dosage:3, 30, 300 μg/L in drinking water
-
Administration:p.o. from mating through gestation, lactation and until 30 weeks of age
-
Result:Increased pancreatic insulitis grade at 11 weeks of age (300 μg/L).
Increased number of apoptotic cells in pancreatic islets with insulitis grade 0 at 11 weeks of age (300 μg/L).
Reduced peritoneal macrophage phagocytosis at 7 weeks of age (300 μg/L).
Increased ConA-induced IL-2 secretion and decreased LPS-induced IL-6 secretion in splenocytes at 11 weeks of age (3 μg/L).
Showed a trend of increased ConA-induced IL-6 and IFN-γ secretion in splenocytes at 11 weeks of age (300 μg/L).
Had no significant effect on accelerating diabetes development, and low doses (3, 30 μg/L) tended to reduce diabetes incidence.
-
Animal Model:Male Swiss mice (8 or 13 weeks old)[4]
-
Dosage:0.1, 0.3, 0.5, 0.7, 1.0 mg/kg
-
Administration:p.o. for 28-35 days
-
Result:Induced significant hepatic DNA damage.
Caused reproductive toxicity: reduced sperm count and motility, increased sperm abnormalities; elevated serum LH and FSH, reduced testosterone; testicular atrophy and histopathological lesions.
Altered hematological parameters: decreased PCV, Hb, platelets, RBC count and indices; increased WBC and neutrophils.
Disrupted clinical biochemistry: elevated AST, ALT, urea, total cholesterol, triglyceride; reduced ALP, albumin, creatinine, HDL.
Induced oxidative stress in liver and testis: increased SOD, CAT, GST, MDA; reduced GPx, GSH.
Caused histopathological lesions in liver (cellular infiltration, venous congestion) and kidney (interstitial congestion, tubular lumen expansion); no spleen lesions.
Chemical Information
-
CAS No. 2058-94-8
-
Appearance Solid
-
Molecular Weight 564.09
-
Formula C11HF21O2
-
Color White to off-white
-
SMILES
O=C(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(F)F)F)F)F)F)F)F)F)F)F)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 175 mg/mL (310.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cui Z, et al. PFDA promotes cancer metastasis through macrophage M2 polarization mediated by Wnt/β-catenin signaling. Chemosphere. 2024 Aug;362:142758. [Content Brief]
[2]. Yan H, et al. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Toxicol Appl Pharmacol. 2021 Mar 15;415:115440. [Content Brief]
[3]. Bodin J, et al. Exposure to perfluoroundecanoic acid (PFUnDA) accelerates insulitis development in a mouse model of type 1 diabetes. Toxicol Rep. 2016 Aug 29;3:664-672. [Content Brief]
[4]. Ogunsuyi OM, et al. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Chemosphere. 2023 Oct;338:139491. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7728 mL | 8.8638 mL | 17.7277 mL | 44.3192 mL |
| 5 mM | 0.3546 mL | 1.7728 mL | 3.5455 mL | 8.8638 mL | |
| 10 mM | 0.1773 mL | 0.8864 mL | 1.7728 mL | 4.4319 mL | |
| 15 mM | 0.1182 mL | 0.5909 mL | 1.1818 mL | 2.9546 mL | |
| 20 mM | 0.0886 mL | 0.4432 mL | 0.8864 mL | 2.2160 mL | |
| 25 mM | 0.0709 mL | 0.3546 mL | 0.7091 mL | 1.7728 mL | |
| 30 mM | 0.0591 mL | 0.2955 mL | 0.5909 mL | 1.4773 mL | |
| 40 mM | 0.0443 mL | 0.2216 mL | 0.4432 mL | 1.1080 mL | |
| 50 mM | 0.0355 mL | 0.1773 mL | 0.3546 mL | 0.8864 mL | |
| 60 mM | 0.0295 mL | 0.1477 mL | 0.2955 mL | 0.7387 mL | |
| 80 mM | 0.0222 mL | 0.1108 mL | 0.2216 mL | 0.5540 mL | |
| 100 mM | 0.0177 mL | 0.0886 mL | 0.1773 mL | 0.4432 mL |